Your shopping cart is empty
Subscriber login
REGISTER FOR FREE EZINES
Advanced Search
- Please Select -
Regulation
Business Development
Drug Manufacturing
Device Manufacturing
Quality Management
Home
Books
Conferences
DVDs
Newsletters
Form 483
s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us
Check out our free and informative ezines and sign up now
Sign Up
Home
>
Newsletters
>
The QMN Weekly Bulletin
> FDA Warns Luitpold Over Drug Manufacturing Violations
The QMN Weekly Bulletin
Sept. 16, 2011
| Vol. 3 No. 37
FDA Warns Luitpold Over Drug Manufacturing Violations
The U.S. Food and Drug Administration warned Luitpold Pharmaceuticals to fix significant problems at a plant temporarily shut down in April after inspectors found violations.
Law360
Register Now
Print This Page
Email This Article
RSS
Archives
Related Articles
Gilead Form 483 Provides Insight Into FDA’s Rejection of HIV Drugs
UDI Final Rule Takes Industry Advice, But Will Still Pose Challenges: Experts
Baxter Warned Over Contamination, GMP Deviations at Two Plants
China, India Fine-Tuning GMPs as API Makers Rush to Meet New EU Rules